Related Experiment Videos
Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction
D Hasdai1, R M Califf, T D Thompson
1Rabin Medical Center, Petah Tikva, Israel.
Insights
A new scoring system accurately predicts cardiogenic shock risk after acute myocardial infarction (AMI) treatment. Key factors include patient age and physical exam findings, aiding early intervention for better outcomes.
Area of Science:
- Cardiology
- Clinical Medicine
- Medical Research
Background:
- Cardiogenic shock is a severe complication of acute myocardial infarction (AMI).
- Early identification of high-risk patients is crucial for implementing preventive strategies.
- Thrombolytic therapy is a standard treatment for AMI, but carries risks.
Purpose of the Study:
- To identify clinical factors predicting cardiogenic shock post-thrombolytic therapy for AMI.
- To develop and validate a predictive scoring system for cardiogenic shock risk.
- To improve patient management by identifying those at high risk for shock.
Main Methods:
- Analysis of baseline variables from the GUSTO-I trial cohort.
- Development of a Cox proportional hazards model to predict shock risk.
- Validation of the predictive model in the GUSTO-III cohort.
Main Results:
- Age, systolic blood pressure, heart rate, and Killip class were major predictors of shock.
- These four variables explained over 85% of the predictive information in GUSTO-I.
- The validated model showed strong predictive accuracy (concordance index 0.796 in GUSTO-III).
Conclusions:
- A simple scoring system based on age and physical examination accurately predicts shock risk after AMI.
- This tool can aid clinicians in identifying high-risk patients for targeted interventions.
- The findings support the use of this scoring system in clinical practice for AMI management.
Objectives:
This study characterized clinical factors predictive of cardiogenic shock developing after thrombolytic therapy for acute myocardial infarction (AMI).
Background:
Cardiogenic shock remains a common and ominous complication of AMI. By identifying patients at risk of developing shock, preventive measures may be implemented to avert its development.
Methods:
We analyzed baseline variables associated with the development of shock after thrombolytic therapy in the Global Utilization of Streptikonase and Tissue-Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. Using a Cox proportional hazards model, we devised a scoring system predicting the risk of shock. This model was then validated in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) cohort.
Results:
Shock developed in 1,889 patients a median of 11.6 h after enrollment. The major factors associated with increased adjusted risk of shock were age (chi2 = 285, hazard ratio [95% confidence interval] 1.47 [1.40, 1.53]), systolic blood pressure (chi2 = 280), heart rate (chi2 = 225) and Killip class (chi2 = 161, hazard ratio 1.70 [1.52, 1.90] and 2.95 [2.39, 3.63] for Killip II versus I and Killip III versus I, respectively) upon presentation. Together, these four variables accounted for >85% of the predictive information. These findings were transformed into an algorithm with a validated concordance index of 0.758. Applied to the GUSTO-III cohort, the four variables accounted for > 95% of the predictive information, and the validated concordance index was 0.796.
Conclusions:
A scoring system accurately predicts the risk of shock after thrombolytic therapy for AMI based primarily on the patient's age and physical examination on presentation.